MedTrace Logo

Artoss Foot and Ankle Surgery Registry

NCT04503759 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-05-13

No results posted yet for this study

Summary

This prospective registry was designed as an observational study to ascertain how commercially available NanoBone products are being used by surgeons performing foot and ankle surgery which involves bone grafting, as well as determining relevant patient outcomes.

Conditions

  • Arthritis Foot
  • Trauma Injury
  • Deformity; Bone

Interventions

OTHER

NanoBone Bone Graft Substitute

Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.

Sponsors & Collaborators

  • Artoss Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Cassidy, PhD · Artoss Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2024-05-10
Completion
2024-05-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04503759 on ClinicalTrials.gov